<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30077429</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>05</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1938-0666</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Clinical breast cancer</Title>                <ISOAbbreviation>Clin. Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S1526-8209(18)30009-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clbc.2018.07.008</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2<sup>+</sup>) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic complete response (pCR) rate for trastuzumab and pertuzumab (HP)-containing regimens compared with trastuzumab (H)-containing regimens for stage II to III HER2<sup>+</sup> BC.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients (n = 977) with stage II to III HER2<sup>+</sup> BC who received neoadjuvant HER2-targeted therapy from 2005 to 2016 and underwent definitive breast and axillary lymph node surgery were identified. pCR was defined as ypT0/is, ypN0. Univariate/multivariate logistic regression and the χ<sup>2</sup> test for comparing proportions was used for the statistical analysis.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The pCR rate was higher for the HP group (n = 170) compared with the H group (n = 807): 59% versus 46% (odds ratio, 1.7; 95% confidence interval, 1.21-2.37; P = .0021). After adjustment for clinically important factors (age, date of diagnosis, stage, tumor grade, nodal status, hormone receptor [HR] status, menopausal status, and chemotherapy backbone) the adjusted odds ratio was 2.25 (95% confidence interval, 1.08-4.73; P = .032). In multivariate analysis, a significant predictor of pCR in both groups included HR status (HR-negative &gt; HR-positive).</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate that HP-containing regimens yield higher pCR rates compared with H-containing regimens in patients with stage II to III HER2<sup>+</sup> BC in clinical practice regardless of chemotherapy backbone.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Murthy</LastName>                    <ForeName>Rashmi K</ForeName>                    <Initials>RK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rmurthy1@mdanderson.org.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Raghavendra</LastName>                    <ForeName>Akshara S</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hess</LastName>                    <ForeName>Kenneth R</ForeName>                    <Initials>KR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fujii</LastName>                    <ForeName>Takeo</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Bora</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Barcenas</LastName>                    <ForeName>Carlos H</ForeName>                    <Initials>CH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Hong</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Cancer Prevention, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chavez-Mac-Gregor</LastName>                    <ForeName>Mariana</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mittendorf</LastName>                    <ForeName>Elizabeth A</ForeName>                    <Initials>EA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Litton</LastName>                    <ForeName>Jennifer K</ForeName>                    <Initials>JK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giordano</LastName>                    <ForeName>Sharon H</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thompson</LastName>                    <ForeName>Alastair M</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Valero</LastName>                    <ForeName>Vicente</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moulder</LastName>                    <ForeName>Stacy L</ForeName>                    <Initials>SL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tripathy</LastName>                    <ForeName>Debu</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ueno</LastName>                    <ForeName>Naoto T</ForeName>                    <Initials>NT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Clin Breast Cancer</MedlineTA>            <NlmUniqueID>100898731</NlmUniqueID>            <ISSNLinking>1526-8209</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Neoadjuvant</Keyword>            <Keyword MajorTopicYN="N">Pathologic complete response</Keyword>            <Keyword MajorTopicYN="N">Pertuzumab</Keyword>            <Keyword MajorTopicYN="N">Trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30077429</ArticleId>            <ArticleId IdType="pii">S1526-8209(18)30009-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.clbc.2018.07.008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>